Genmab A/S is a biotechnology business based in the US. Genmab A/S shares (GMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Genmab A/S employs 871 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Genmab A/S
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GMAB – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- GMAB shares summary
- Compare share dealing platforms
- Is GMAB stock a buy or sell?
- Stock performance over time
- Can I short GMAB shares?
- Are GMAB shares over-valued?
- Genmab A/S's financials
- How volatile are GMAB shares?
- Does Genmab A/S pay a dividend?
- Have GMAB shares ever split?
- Other common questions
Genmab A/S stock price (NASDAQ: GMAB)Use our graph to track the performance of GMAB stocks over time.
Genmab A/S shares at a glance
|Latest market close||$40.62|
|52-week range||$30.10 - $45.48|
|50-day moving average||$43.18|
|200-day moving average||$38.74|
|Wall St. target price||$42.21|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.35|
Buy Genmab A/S shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Genmab A/S stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Genmab A/S price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||-2.24%|
|3 months (2021-04-30)||10.17%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
Is Genmab A/S under- or over-valued?
Valuing Genmab A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genmab A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genmab A/S's P/E ratio
Genmab A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, Genmab A/S shares trade at around 33x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Genmab A/S's PEG ratio
Genmab A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 13.2792. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Genmab A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Genmab A/S's EBITDA
Genmab A/S's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $7 billion.
The EBITDA is a measure of a Genmab A/S's overall financial performance and is widely used to measure a its profitability.
Genmab A/S financials
|Revenue TTM||$10.8 billion|
|Operating margin TTM||62.93%|
|Gross profit TTM||$10.1 billion|
|Return on assets TTM||22.65%|
|Return on equity TTM||32.38%|
|Market capitalisation||$29.5 billion|
TTM: trailing 12 months
Shorting Genmab A/S shares
There are currently 1.6 million Genmab A/S shares held short by investors – that's known as Genmab A/S's "short interest". This figure is 14.6% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting Genmab A/S shares can be evaluated.
Genmab A/S's "short interest ratio" (SIR)
Genmab A/S's "short interest ratio" (SIR) is the quantity of Genmab A/S shares currently shorted divided by the average quantity of Genmab A/S shares traded daily (recently around 699618.45493562). Genmab A/S's SIR currently stands at 2.33. In other words for every 100,000 Genmab A/S shares traded daily on the market, roughly 2330 shares are currently held short.
However Genmab A/S's short interest can also be evaluated against the total number of Genmab A/S shares, or, against the total number of tradable Genmab A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genmab A/S's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Genmab A/S shares in existence, roughly 0 shares are currently held short) or 0.0025% of the tradable shares (for every 100,000 tradable Genmab A/S shares, roughly 3 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genmab A/S.
Find out more about how you can short Genmab A/S stock.
Genmab A/S share dividends
We're not expecting Genmab A/S to pay a dividend over the next 12 months.
Have Genmab A/S's shares ever split?
Genmab A/S's shares were split on a 5:1 basis on 30 April 2018. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Genmab A/S shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Genmab A/S shares which in turn could have impacted Genmab A/S's share price.
Genmab A/S share price volatility
Over the last 12 months, Genmab A/S's shares have ranged in value from as little as $30.1 up to $45.4799. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genmab A/S's is 0.5866. This would suggest that Genmab A/S's shares are less volatile than average (for this exchange).
Genmab A/S overview
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.
Stocks similar to Genmab A/S
Genmab A/S in the news
2 Biotech Stocks to Buy for Outsized Gains
Denmark stocks higher at close of trade; OMX Copenhagen 20 up 0.23% By Investing.com
Major Shareholder Announcement
Frequently asked questionsWhat percentage of Genmab A/S is owned by institutions?
Currently 7.033% of Genmab A/S shares are held by institutions. How many people work for Genmab A/S?
Latest data suggests 871 work at Genmab A/S. When does the fiscal year end for Genmab A/S?
Genmab A/S's fiscal year ends in December. Where is Genmab A/S based?
Genmab A/S's address is: Kalvebod Brygge 43, Copenhagen, Denmark, 1560 What is Genmab A/S's ISIN number?
Genmab A/S's international securities identification number is: US3723032062 What is Genmab A/S's CUSIP number?
Genmab A/S's Committee on Uniform Securities Identification Procedures number is: 372303206
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert